目的：探讨ＩＬ６在卵巢上皮癌中的临床价值。方法：通过对４０例卵巢癌患者血清、腹水中白细胞介素６（Ｉｎｔｅｒｌｅｕｋｉｎ６，ＩＬ６）进行生物活性测定。结果：１、腹水中ＩＬ６水平明显高于血清中ＩＬ６水平（Ｐ＜０００１）；２、腹水或血清中ＩＬ６水平与卵巢癌分期呈正相关；３、卵巢癌术后残留与ＩＬ６水平呈正相关；４、腹水中ＩＬ６水平影响患者对卡铂化疗敏感性。结论：腹水或血清中ＩＬ６生物活性的测定有可能成为卵巢癌疾病状态的评估及选择化疗药物的根据。 Objective: To investigate the clinical value of IL6 in epithelial ovarian cancer. Methods: The biological activity of interleukin6 (Interleukin6, IL6) in serum and ascites of 40 patients with ovarian cancer was determined. IL-6 levels in ascites were significantly higher than serum IL-6 levels (P <0001); 2, ascites or serum IL 6 levels and ovarian cancer staging was positively correlated; 3, ovarian cancer postoperative Residues and IL 6 levels were positively correlated; 4, ascites IL 6 levels in patients with carboplatin chemotherapy sensitivity. Conclusion: The determination of the biological activity of IL6 in ascites or serum may become the basis for evaluating the status of ovarian cancer and selecting chemotherapy drugs.